Novo’s oral semaglutide on target in phase 3 trialNovo Nordisk continues to build a case for its oral semaglutide GLP-1 class diabetes drug, with latest results Share XNovo’s oral semaglutide on target in phase 3 trialhttps://pharmaphorum.com/news/novos-oral-semaglutide-target-phase-3-trial/
